The Federal Antimonopoly Service announced a reduction in the price of four vital medicines

In Russia, prices have been reduced for 4 more essential medicines (VED). Among them are medicines for the treatment of respiratory tract diseases, lymphoma, breast cancer, tachycardia and hypertension, the FAS press service reported on March 28.

We are talking about (original) medicines with the international nonproprietary name (INN) Alpelisib, Zanubrutinib, Beclomethasone+Glycopyrronium bromide+Formoterol" and a reproduced drug with INN "Esmolol", which were included in the list of VED in 2025.

"The FAS conducted an economic analysis of producer prices for these drugs, as a result of which they were reduced by an average of 25% of the average cost of their sale in 2024 and by an average of 37% of the minimum prices in the countries of reference for Russia. The antitumor drug Picray (INN Alpelisib) is used for hormone-dependent breast cancer. Its price is 52% lower than the minimum cost in the reference countries for Russia and 16% lower than the average selling price of the drug in 2024," the FAS said.

The price of the antitumor drug "Brookinza" (INN "Zanubrutinib") is 31% lower than the minimum cost in the countries of reference for Russia, and 7% lower than the average selling price in 2024. This drug is used to treat mantle cell lymphoma (MCL) in adults who have already undergone at least one previous therapy.

Foregone bargaining: FAS found collusion in the supply of vital drugs

We are talking about contracts worth hundreds of millions of rubles

The drug "Trimbow" (INN "Beclomethasone+Glycopyrronium bromide+Formoterol") is intended for the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma. Its price has been reduced by 28% compared to the average cost of sales in 2024, as well as by the same amount relative to the minimum price in the countries of reference for Russia.

Prices for the domestic generic Brevicard (INN Esmolol), indicated for supraventricular tachycardia and for the correction of tachycardia and hypertension, are agreed to be 20% lower than the minimum price of the original Breviblock drug in the countries of reference for Russia and 37% lower than the average cost of its sale in 2024.

"Reducing the cost of drugs will increase their accessibility for Russian citizens. In medical organizations, they should be provided to citizens free of charge as part of the program of state guarantees of free medical care," the press service of the department said.

Earlier, on February 5, the press service of the CRPT informed Izvestia about 540 new medicines. It was clarified that the new international nonproprietary names (INN) belong to various pharmacological groups. These include sex hormones and modulators of genital function (20% of the total volume of new INN), vitamins (17%), antitussive drugs and drugs for the treatment of colds (10%), muscle relaxants (10%), as well as drugs for the treatment of diseases associated with impaired acidity (8%).